000			03923nam a22003975i 4500
999			_c81310 _d81310 _x1
001			81310
003			ES-MaUEC
005			20230207040323.0
006			a||||fo|||| 00| 0
007			cr nn 008mamaa
008			150305s2015 gw | s |||| 0|eng d
020			_a9783319130811
024	7		_a10.1007/978-3-319-13081-1 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRS201.A56 _b2015 EB
245	1	0	_aAntibody-Drug Conjugates : _bThe 21st Century Magic Bullets for Cancer _cedited by Jeffrey Wang, Wei-Chiang Shen, Jennica L. Zaro.
260			_aCham, Switzerland _bSpringer _c2015
300			_a1 recurso en línea (X, 252 p.) _b59 ilustraciones, 32 ilustraciones en color
336			_aTexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
490	1		_aAAPS Advances in the Pharmaceutical Sciences Series _x2210-7371 _v17
505	0		_a1 Antibody-Drug Conjugates: A Historical Review -- 2 Payloads of Antibody-Drug Conjugates -- 3 Selecting an Optimal Antibody for Antibody-Drug Conjugate Therapy -- 4 Linker Design for Antibody-Drug Conjugates -- 5 Formulation Development for Antibody-Drug Conjugates -- 6 Bioanalytical Assay for Characterization of Antibody Drug Conjugates -- 7 Pharmacokinetics/Pharmacodynamics and Disposition of Antibody-Drug Conjugates -- 8 Regulatory Considerations -- 9 Major ADC Companies, Current Clinical Trials, Recent Patents Issued and Patent Applications, and Cost Analysis of Drug Therapy -- 10 Mylotarg: Revisiting its Clinical Potential Post-Withdrawal -- 11 ADCETRIS: A Regulatory Case Study of a New Generation Antibody Drug Conjugate -- 12 Ado-Trastuzumab Emtansine -- 13 The Antibody-Drug Conjugate Glembatumumab Vedotin (CDX-011) and its Use in Treatment of Breast Cancer -- 14 Summary and Future Directions.
520			_aThis authoritative volume provides a holistic picture of antibody-drug conjugates (ADCs). Fourteen comprehensive chapters are divided into six sections including an introduction to ADCs, the ADC construct, development issues, landscape, IP and pharmacoeconomics, case studies, and the future of the field. The book examines everything from the selection of the antibody, the drug, and the linker to a discussion of developmental issues such as formulations, bio-analysis, pharmacokinetic-pharmacodynamic relationships, and toxicological and regulatory challenges. It also explores pharmacoecomonics and intellectual properties, including recently issued patents and the cost analysis of drug therapy. Case studies are presented for the three ADCs that have received FDA approval: gemtuzumab ozogamicin (Mylotarg®), Brentuximab vedotin (Adcetris®), and ado-trastuzumab emtansine (Kadcyla®), as well as an ADC in late-stage clinical trials, glembatumumab vedotin (CDX-011). Finally, the volume presents a perspective by the editors on the future directions of ADC development and clinical applications. Antibody-Drug Conjugates is a practical and systematic resource for scientists, professors, and students interested in expanding their knowledge of cutting-edge research in this exciting field.
988			_aEBOOK, EBSPRINGER
650		7	_9405730 _aAnticuerpos monoclonales _2embne
650		7	_9174085 _aCáncer _2embne _xTratamiento
700	1		_aWang, Jeffrey _eeditor literario _993667 _0Local
700	1		_aShen, Wei-Chiang _eeditor literario _993668 _0Local
700	1		_aZaro, Jennica L _eeditor literario _993669 _0Local
710	2		_aSpringerLink (Online service) _0Local _9106996
830		0	_aAAPS Advances in the Pharmaceutical Sciences Series _x2210-7371 _v17 _9133175
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-3-319-13081-1 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b10/2020 _dz _eIG _feng _ggw _h0